In a breakthrough that promises to reshape the therapeutic landscape for locally advanced lung cancer, researchers have unveiled compelling data from the AFT-46/CHIO3 clinical trial, revealing that the strategic combination of chemotherapy with immunotherapy prior to surgery significantly enhances outcomes for patients with stage III non-small cell lung cancer (NSCLC) involving mediastinal lymph nodes (N2+). This landmark study, led by Dr. Linda W. Martin, MD, MPH, Professor of Thoracic Surgery at the University of Virginia, and published in the journal Lung Cancer, underscores a paradigm shift in managing a challenging subset of lung cancer traditionally marred by poor prognosis and limited surgical options.
NSCLC with N2 lymph node involvement has long been intractable, as tumor infiltration into central thoracic structures often precludes complete surgical resection, a key determinant of patient survival. Historically, neoadjuvant chemotherapy—with or without radiation—offered minimal success in downstaging tumors to operability, frequently culminating in partial resections or inoperability, with consequent suboptimal long-term results. Recognizing this therapeutic impasse, the CHIO3 trial sought to harness the immune system’s potential through immune checkpoint blockade, using durvalumab, in concert with conventional chemotherapeutic agents, aiming to potentiate tumor regression pre-surgery and improve surgical resectability rates.
Between 2021 and 2023, the multi-institutional trial enrolled patients diagnosed with stage III, N2+ NSCLC across nine premier centers spanning Illinois, Massachusetts, New York, Tennessee, and Virginia. The treatment regimen entailed an initial phase of combined chemotherapy and durvalumab administration, targeting tumor burden reduction and lymph node clearance, followed by surgical intervention. Crucially, post-operative management included a one-year course of durvalumab to consolidate immune-mediated tumor surveillance and inhibit relapse. This comprehensive approach integrates the cytotoxic impact of chemotherapy with immunotherapy’s precision immune activation, representing a new therapeutic blueprint.
Results from the trial revealed that an impressive 81% of enrolled patients proceeded to surgery post combination therapy, a significant improvement compared to historical controls relying solely on chemotherapy. Astonishingly, among those undergoing resection, approximately 73% exhibited complete eradication of cancer cells from mediastinal lymph nodes, a feature rarely achieved by chemotherapy alone. Furthermore, around 30% of surgical specimens displayed a pathological complete response (pCR), devoid of any viable cancer cells, highlighting the robust anti-tumor efficacy engendered by the immunochemotherapeutic synergy.
Surgical outcomes were equally promising, with 93% of operated patients achieving complete tumor removal with negative margins, a crucial factor in reducing recurrence risk. One and a half years into follow-up, survival data showed all patients who underwent resection remained alive, suggesting not only enhanced resectability but also potentially improved overall survival and disease-free intervals. These findings illuminate the transformative potential of integrating immunotherapy into neoadjuvant regimens for resectable locally advanced NSCLC, offering renewed hope where therapeutic options were historically exhausted.
Dr. David Kozono, MD, PhD, Director of the Alliance Foundation and Thoracic Radiation Oncology at Mass General Brigham Cancer Center, emphasized the novelty of this trial’s focus on lymph node clearance, pointing out that “to our knowledge, this is the first trial specifically focused on lymph node clearance in this population.” The enhanced rates of nodal clearance coupled with successful surgical resection firmly establish this combinatorial approach as a pivotal advance in the multidisciplinary treatment of stage III lung cancer.
The mechanistic rationale for combining chemotherapy with immune checkpoint inhibition lies in chemotherapy’s ability to induce immunogenic cell death, releasing tumor-associated antigens and modulating the tumor microenvironment, thereby sensitizing cancer cells to immunotherapy. Durvalumab, an anti-PD-L1 immune checkpoint inhibitor, disrupts the tumor’s immune evasion tactics, revitalizing cytotoxic T lymphocyte responses. The resultant synergistic effect facilitates more effective tumor debulking and lymph node sterilization prior to resection, augmenting long-term oncologic control.
Going forward, the clinical team will continue to longitudinally monitor trial participants to assess the durability of response, incidence of recurrence, and any long-term adverse effects associated with the regimen. The potential for lymph node clearance to serve as an early surrogate biomarker for improved survival holds promise for refining patient selection and optimizing personalized treatment pathways. Further analyses integrating immune profiling and molecular tumor characterization are anticipated to elucidate predictors of response, thereby fine-tuning therapeutic algorithms.
This study received support from the Alliance Foundation Trials and the Alliance for Clinical Trials in Oncology Foundation, with AstraZeneca providing durvalumab and funding. Rigorous oversight was maintained throughout the trial via Institutional Review Boards and the Data and Safety Monitoring Board to ensure ethical compliance and participant safety. All patients provided informed consent, reaffirming the commitment to ethical standards in oncologic research.
The findings from the CHIO3 trial herald a significant advance in lung cancer therapy, demonstrating that the integration of immunotherapy into neoadjuvant treatment regimens can achieve remarkable rates of tumor and lymph node clearance, enabling more patients to benefit from curative surgery. As the oncology community awaits long-term survival data, this approach may soon redefine standards of care for a historically formidable clinical challenge, offering renewed hope for patients afflicted with locally advanced NSCLC.
Subject of Research: People
Article Title: CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)
News Publication Date: 1-May-2026
Web References:
AFT-46 Clinical Trial
References:
CHIO3 Study in Lung Cancer Journal – DOI: 10.1016/j.lungcan.2026.109374
Image Credits: UVA (University of Virginia)
Keywords:
Lung cancer, Non-small cell lung cancer, Stage III NSCLC, N2 lymph nodes, Chemotherapy, Immunotherapy, Durvalumab, Immune checkpoint inhibitor, Neoadjuvant therapy, Surgical resection, Pathologic complete response, Lymph node clearance, Cancer immunotherapy
